Prostate cancer: real-world QoL data favor abiraterone over enzalutamide

  • Thiery-Vuillemin A & et al.
  • Eur Urol.
  • 5 Oct 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Real-world 12-month data suggest abiraterone is associated with superior QoL vs enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).

Why this matters

  • Findings in line with meta-analyses of 4 randomized studies (COU-AA-301, COU-AA-302, AFFIRM, and PREVAIL).
  • Clinicians should consider treatment effects on patient QoL.

Study design

  • 12-month AQUARiUS observational study of 226 patients with mCRPC received abiraterone or enzalutamide.
  • Outcome: patient-reported outcomes evaluated in four 3-month periods.
  • Funding: Janssen EMEA.

Key results

  • Overall treatment duration was 38.3 weeks in the abiraterone group and 38.7 weeks in the enzalutamide group.
  • Abiraterone group showed significantly improved 18 of 28 patient-reported outcome (PRO) items vs enzalutamide (P<.05>
  • 9 PRO items were statistically significant in favor of abiraterone for ≥3 periods.
    • These PROs were linked to cognition, fatigue, appetite loss, and nausea.
  • 69% of patients reported ≥1 adverse event with abiraterone and 77% with enzalutamide.
  • Abiraterone group reported lower incidence of fatigue (5% vs 15%) and asthenia (10% vs 11%).

Limitations

  • Observational nonrandomized study.